{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:55:01Z","timestamp":1791568501121,"version":"4.3.4"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Daily preexposure prophylaxis (PrEP) use can prevent up to 99% of HIV infections; however, PrEP uptake is low due to poor access to PrEP-prescribing locations for populations at increased risk for HIV, especially in the southeastern US. Pharmacies are a feasible option to increase PrEP access, but little is known about how they could complement current PrEP-prescribing locations.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine geographic distributions of current PrEP-prescribing locations compared with pharmacies and the facility to need ratios (PFNRs) according to HIV risk in the Southeast and describe the potential reach of pharmacies to expand PrEP access.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Data for this cross-sectional study of PrEP-prescribing locations and pharmacies were compiled from January 1 to December 31, 2021. States or specific counties in the Southeast included in this study were jurisdictions identified as high-priority areas for the Ending the HIV Epidemic in the US (EHE) initiative.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Expansion of HIV prevention services to pharmacies.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Choropleth maps of 5-year HIV risk per 100\u202f000 persons were developed for EHE jurisdictions in the southeastern US. PrEP-prescribing locations (obtained from a national database of PrEP prescribers) and pharmacies (obtained from state pharmacy boards) were overlayed on HIV risk maps. The PFNRs by state were calculated as number of facilities (PrEP-prescribing locations or pharmacies) divided by 5-year HIV risk per 100\u202f000 persons. Lower PFNRs indicated lower geographic availability of locations to meet the needs of the population at risk for HIV. The PFNRs for current PrEP-prescribing locations vs pharmacies were compared.<\/jats:p><\/jats:sec>Results<\/jats:title>Among the 2 southeastern states and 13 counties in 4 southeastern states included, PrEP-prescribing locations were unequally distributed across EHE areas, with substantially fewer in areas at high risk for HIV. Pharmacies were evenly dispersed across areas regardless of HIV risk. The mean PFNR across all states for current PrEP-prescribing locations was 0.008 (median, 0.000 [IQR, 0.000-0.003]); for pharmacies, it was 0.7 (median, 0.3 [IQR, 0.01-0.1]). The PFNRs were at least 20.3 times higher for pharmacies compared with PrEP-prescribing locations. States with the greatest potential increase in PFNRs with expansion to pharmacies included Kentucky, South Carolina, and Tennessee.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings of this cross-sectional study suggest that expanding HIV prevention services to pharmacies in EHE areas in the Southeast could significantly increase capacity to reach individuals at increased risk of HIV transmission. Legislation aimed at allowing pharmacists to prescribe PrEP and provide HIV prevention services may be an important next step in ending the HIV epidemic.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.26028","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T15:32:33Z","timestamp":1690471953000},"page":"e2326028","source":"Crossref","is-referenced-by-count":20,"title":["Examination of HIV Preexposure Prophylaxis Need, Availability, and Potential Pharmacy Integration in the Southeastern US"],"prefix":"10.1001","volume":"6","author":[{"given":"Kristin R. V.","family":"Harrington","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia"},{"name":"Department of Medicine, Emory University School of Medicine, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Chandra","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel I.","family":"Alohan","sequence":"additional","affiliation":[{"name":"Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cruz","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron J.","family":"Siegler","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie D.","family":"Crawford","sequence":"additional","affiliation":[{"name":"Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"issue":"41","key":"zoi230748r3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.15585\/mmwr.mm6741a3","article-title":"HIV preexposure prophylaxis, by race and ethnicity\u2014United States, 2014-2016.","volume":"67","author":"Huang","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"18","key":"zoi230748r4","doi-asserted-by":"publisher","first-page":"9715","DOI":"10.3390\/ijerph18189715","article-title":"Pre-exposure prophylaxis (PrEP) uptake among black men who have sex with men (BMSM) in the Southern US.","volume":"18","author":"Adeagbo","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"9","key":"zoi230748r5","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.2105\/AJPH.2019.305172","article-title":"Geographic access to preexposure prophylaxis clinics among men who have sex with men in the United States.","volume":"109","author":"Siegler","year":"2019","journal-title":"Am J Public Health"},{"issue":"12","key":"zoi230748r6","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.annepidem.2018.05.006","article-title":"Location location location: an exploration of disparities in access to publicly listed pre-exposure prophylaxis clinics in the United States.","volume":"28","author":"Siegler","year":"2018","journal-title":"Ann Epidemiol"},{"issue":"8","key":"zoi230748r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.22692","article-title":"Characterization of HIV preexposure prophylaxis use behaviors and HIV incidence among US adults in an integrated health care system.","volume":"4","author":"Hojilla","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi230748r8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.22454\/FamMed.2022.740210","article-title":"HIV preexposure prophylaxis training in family medicine residencies: a national survey.","volume":"54","author":"Jasper","year":"2022","journal-title":"Fam Med"},{"issue":"8","key":"zoi230748r9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183172","article-title":"The availability of pharmacies in the United States: 2007-2015.","volume":"12","author":"Qato","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"zoi230748r11","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.cptl.2020.04.007","article-title":"Evaluation of human immunodeficiency virus curricular content in schools of pharmacy in the United States.","volume":"12","author":"Rathbun","year":"2020","journal-title":"Curr Pharm Teach Learn"},{"issue":"1","key":"zoi230748r17","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.japh.2021.08.001","article-title":"An observational survey assessing the extent of PrEP and PEP furnishing in San Francisco Bay Area pharmacies.","volume":"62","author":"Bellman","year":"2022","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"9","key":"zoi230748r19","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1177\/1060028016653608","article-title":"The continuum of pharmacist prescriptive authority.","volume":"50","author":"Adams","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"2","key":"zoi230748r20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/QAI.0000000000001495","article-title":"Estimated HIV incidence, prevalence, and undiagnosed infections in US States and Washington, DC, 2010-2014.","volume":"76","author":"Satcher Johnson","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"zoi230748r23","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1097\/QAI.0000000000001706","article-title":"Users of a national directory of PrEP service providers: beliefs, self-efficacy, and progress toward prescription.","volume":"78","author":"Bratcher","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"zoi230748r24","doi-asserted-by":"publisher","DOI":"10.2196\/publichealth.7902","article-title":"Developing a Web-based geolocated directory of HIV pre-exposure prophylaxis-providing clinics: the PrEP Locator protocol and operating procedures.","volume":"3","author":"Siegler","year":"2017","journal-title":"JMIR Public Health Surveill"},{"issue":"10","key":"zoi230748r25","doi-asserted-by":"publisher","DOI":"10.2196\/23173","article-title":"A data visualization and dissemination resource to support HIV prevention and care at the local level: analysis and uses of the AIDSVu Public Data Resource.","volume":"22","author":"Sullivan","year":"2020","journal-title":"J Med Internet Res"},{"issue":"2","key":"zoi230748r26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.32614\/RJ-2016-043","article-title":"tigris: An R package to access and work with geographic data from the us census bureau.","volume":"8","author":"Walker","year":"2016","journal-title":"R J"},{"issue":"1","key":"zoi230748r27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.32614\/RJ-2013-014","article-title":"ggmap: Spatial visualization with ggplot2.","volume":"5","author":"Khale","year":"2013","journal-title":"R J"},{"issue":"3","key":"zoi230748r29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/QAI.0000000000002774","article-title":"Trends in the number and characteristics of HIV pre-exposure prophylaxis providers in the United States, 2014-2019.","volume":"88","author":"Zhu","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"zoi230748r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.evalprogplan.2021.101966","article-title":"HIV PrEP implementation: a multi-level systems approach.","volume":"90","author":"Frank","year":"2022","journal-title":"Eval Program Plann"},{"issue":"9","key":"zoi230748r31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238375","article-title":"Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US.","volume":"15","author":"Leech","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"zoi230748r32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s10461-021-03375-w","article-title":"Optimizing provider preexposure prophylaxis (PrEP) training: a cross-sectional analysis of recommendations from providers across the PrEP implementation cascade.","volume":"26","author":"Rao","year":"2022","journal-title":"AIDS Behav"},{"issue":"4","key":"zoi230748r33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1089\/lgbt.2017.0101","article-title":"Missed opportunities to prescribe HIV pre-exposure prophylaxis by primary care providers in Saint Louis, Missouri.","volume":"5","author":"Patel","year":"2018","journal-title":"LGBT Health"},{"issue":"1","key":"zoi230748r34","doi-asserted-by":"publisher","DOI":"10.2196\/12405","article-title":"Spatial access and willingness to use pre-exposure prophylaxis among Black\/African American individuals in the United States: cross-sectional survey.","volume":"5","author":"Ojikutu","year":"2019","journal-title":"JMIR Public Health Surveill"},{"issue":"2","key":"zoi230748r35","doi-asserted-by":"publisher","DOI":"10.2196\/35590","article-title":"Integrating and disseminating pre-exposure prophylaxis (PrEP) screening and dispensing for black men who have sex with men in Atlanta, Georgia: protocol for community pharmacies.","volume":"11","author":"Crawford","year":"2022","journal-title":"JMIR Res Protoc"},{"issue":"6","key":"zoi230748r37","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.japh.2020.03.013","article-title":"Patient perception of community pharmacists prescribing pre-exposure prophylaxis for HIV prevention.","volume":"60","author":"Zhu","year":"2020","journal-title":"J Am Pharm Assoc (2003)"},{"key":"zoi230748r1","volume-title":"HIV Screening and Access to Care: Health Care System Capacity for Increased HIV Testing and Provision of Care","author":"Institute of Medicine","year":"2011"},{"key":"zoi230748r2","unstructured":"Centers for Disease Control and Prevention. PrEP for HIV Prevention in the US. Reviewed November 23, 2021. Accessed March 10, 2022. https:\/\/www.cdc.gov\/nchhstp\/newsroom\/fact-sheets\/hiv\/PrEP-for-hiv-prevention-in-the-US-factsheet.html"},{"key":"zoi230748r10","unstructured":"White House. National HIV\/AIDS Strategy for the United States (2022-2025). 2021. Accessed March 20, 2022. https:\/\/www.whitehouse.gov\/wp-content\/uploads\/2021\/11\/National-HIV-AIDS-Strategy.pdf"},{"key":"zoi230748r12","unstructured":"Centers for Disease Control and Prevention. Free continuing education opportunities. Reviewed March 15, 2023. Accessed January 30, 2023. https:\/\/www.cdc.gov\/hiv\/clinicians\/cme\/index.html"},{"key":"zoi230748r13","unstructured":"California Legislative Information. SB 159 HIV: preexposure and postexposure prophylaxis. October 8, 2019. Accessed January 30, 2021. https:\/\/leginfo.legislature.ca.gov\/faces\/billTextClient.xhtml?bill_id=201920200SB159"},{"key":"zoi230748r14","unstructured":"Oregon State Legislature. HB 2958 enrolled: relating to prescription drugs; and prescribing an effective date. 2021. Accessed January 30, 2021. https:\/\/olis.oregonlegislature.gov\/liz\/2021r1\/Measures\/Overview\/HB2958"},{"key":"zoi230748r15","unstructured":"LegisScan. SB 325\u2014establishes provisions relating to preventing the acquisition of human immunodeficiency virus. June 11, 2021. Accessed March 10, 2023. https:\/\/legiscan.com\/NV\/text\/SB325\/2021"},{"key":"zoi230748r16","unstructured":"Colorado General Assembly. HB20-1061: human immunodeficiency virus infection prevention medications. 2020. Accessed January 30, 2021. https:\/\/leg.colorado.gov\/bills\/hb20-1061"},{"key":"zoi230748r18","unstructured":"Dong? BJ. Are pharmacists prepped for PrEP? March 24, 2022. Accessed May 18, 2023. https:\/\/aidsetc.org\/blog\/are-pharmacists-prepped-prep"},{"key":"zoi230748r21","unstructured":"Centers for Disease Control and Prevention. HIV in the southern United States. September 2019. Accessed January 30, 2021. https:\/\/www.cdc.gov\/hiv\/pdf\/policies\/cdc-hiv-in-the-south-issue-brief.pdf"},{"key":"zoi230748r22","doi-asserted-by":"crossref","unstructured":"Office of Infectious Disease and HIV\/AIDS Policy. What is ending the HIV epidemic? Updated July 1, 2022. Accessed January 30, 2023. https:\/\/www.hiv.gov\/federal-response\/ending-the-hiv-epidemic\/overview","DOI":"10.1093\/med\/9780197679098.003.0001"},{"key":"zoi230748r28","unstructured":"R Project for Statistical Computing. R: a language and environment for statistical computing. 2023. Accessed March 10, 2023. https:\/\/www.r-project.org\/"},{"key":"zoi230748r36","unstructured":"Kelley-Ross One-Step PrEP. One-step to HIV prevention. January 2023. Accessed May 18, 2023. https:\/\/one-step-prep.com\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2807661\/harrington_2023_oi_230748_1689708847.64836.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T23:24:39Z","timestamp":1702855479000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2807661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.26028","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]}}}